Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer.

Researchers are also investigating the PD-1 immune checkpoint inhibitor as treatment before surgical and radiation treatment.

Libtayo (cemiplimab) was cleared in 2018 for treating advanced CSCC in patients who are not candidates for curative surgery ...

US biotech Regeneron Pharmaceuticals has announced detailed analyses from the Phase III C-POST trial, which evaluated PD-1 ...

Libtayo demonstrated a 68% reduction in the risk of disease recurrence or death, the primary endpoint of the trial (p0.0001) Libtayo also demonstrated 80% and 65% reductions in the risk of ...

MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer ...

CHICAGO -- Adjuvant cemiplimab (Libtayo) significantly improved disease-free survival (DFS) compared with placebo in patients ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced detailed analyses from the Phase 3 C-POST trial, which evaluated PD-1 inhibitor Libtayo (cemiplimab)in patients with high-risk cutaneous ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...